The Efficacy and Safety of Sirolimus for Plastic Bronchitis

Last updated: May 8, 2019
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Bronchitis

Treatment

N/A

Clinical Study ID

NCT03942926
PB1
  • Ages > 13
  • All Genders

Study Summary

There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • plastic bronchitis

  • pulmonary lymphatic perfusion syndrome demonstrated on 68Ga-NEB positron emissiontomography (PET)

Exclusion

Exclusion Criteria:

  • Pregnancy and breastfeeding

  • Severe cardiovascular, hepatic and renal dysfunction

  • allergy to sirolimus or 68Ga-NEB

Study Design

Total Participants: 10
Study Start date:
May 06, 2019
Estimated Completion Date:
May 05, 2020

Study Description

Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.